drugset / Trial / NCT03205488
Nilotinib in Parkinson's Disease
Phase 2
Completed
76 enrolled
Northwestern University
Michael J. Fox Foundation for Parkinson's Research · collabUniversity of Iowa · collabUniversity of Rochester · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This study will assess the safety and tolerability of daily oral administration of nilotinib (150-300mg once daily) in Parkinson's Disease.
Timeline
- Start
- 2017-10-16
- Primary completion
- 2019-08-26
- Completion
- 2019-09-28
Publications
- Joshi D, Kulkarni M, Parekh P, Shah S, Greig NH, Acharya S. Targeting protein kinases in Parkinson's disease: the emerging role of phytoconstituents. Nutr Neurosci. 2025 Dec;28(12):1532-1563. doi: 10.1080/1028415X.2025.2531356. Epub 2025 Jul 18.
- Simuni T, Fiske B, Merchant K, Coffey CS, Klingner E, Caspell-Garcia C, Lafontant DE, Matthews H, Wyse RK, Brundin P, Simon DK, Schwarzschild M, Weiner D, Adams J, Venuto C, Dawson TM, Baker L, Kostrzebski M, Ward T, Rafaloff G; Parkinson Study Group NILO-PD Investigators and Collaborators. Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2021 Mar 1;78(3):312-320. doi: 10.1001/jamaneurol.2020.4725.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Nilotinib | Small molecule | 150 mg | Oral |
| Comparator | Nilotinib | Small molecule | 300 mg | Oral |